NASDAQ:CBIO

Crescent Biopharma Q3 2026 Earnings Results & Report

Crescent Biopharma logo
$12.84 +0.44 (+3.51%)
As of 02:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Crescent Biopharma missed analyst earnings expectations but beat on revenue in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.90 versus the -$0.6954 consensus estimate, while revenue of $3.12 million topped the $625 thousand estimate by $2.49 million.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes

Crescent Biopharma EPS Results

Actual EPS
-$0.90
Consensus EPS
-$0.6954
Beat/Miss
Missed by -$0.2046
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Crescent Biopharma Revenue Results

Actual Revenue
$3.12 million
Expected Revenue
$625 thousand
Beat/Miss
Beat by +$2.49 million
YoY Revenue Growth
N/A

Crescent Biopharma Q3 2026 Earnings FAQ

Crescent Biopharma (NASDAQ:CBIO) reported earnings of -$0.90 per share for Q3 2026, missing the consensus estimate of -$0.6954. The report was announced on Thursday, November 12, 2026.

Crescent Biopharma reported revenue of $3.12 million for Q3 2026, against a consensus estimate of $625 thousand.

Crescent Biopharma Earnings Headlines

Crescent Biopharma (NASDAQ:CBIO) Price Target Raised to $40.00
Drama In The Trade Rooms! (Black Friday deal to blame?)
Base Camp Trading's Thomas Wood is giving away his proprietary Snapback Indicator for just $7 this Black Friday. Others paid $500 for it. It's a one-time price with no recurring billing, and the indicator is yours for life. It shows when it's time to sell or go short, and when it makes sense to buy. Check it for a potential Snapback before your next trade.tc pixel
Crescent Biopharma (NASDAQ:CBIO) Shares Gap Up on Analyst Upgrade
See More Crescent Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Crescent Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Crescent Biopharma and other key companies, straight to your email.

About Crescent Biopharma

Crescent Biopharma (NASDAQ:CBIO) is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on antibody-based treatments, including therapies designed to target tumor cells and support the body’s immune response.

The company’s work is directed toward advancing oncology drug candidates through clinical development. Its pipeline and programs may change as research progresses, and its products are investigational rather than established treatments.

Crescent Biopharma is focused on developing its therapies for cancer patients; detailed information about its geographic operations and leadership is not included here.

View Crescent Biopharma Profile